Literature DB >> 32405023

Coronavirus drugs trials must get bigger and more collaborative.

.   

Abstract

Entities:  

Keywords:  Diseases; Ethics; SARS-CoV-2; Vaccines

Mesh：

Substances：

Year:  2020        PMID： 32405023     DOI： 10.1038/d41586-020-01391-9

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  4 in total

1.  When Can We Rely on Real-World Evidence to Evaluate New Medical Treatments?

Authors:  Gregory E Simon; Richard Platt; Jonathan H Watanabe; Andrew B Bindman; Alex John London; Michael Horberg; Adrian Hernandez; Robert M Califf
Journal:  Clin Pharmacol Ther       Date:  2021-05-19       Impact factor: 6.903

Review 2.  Collaborative Platform Trials to Fight COVID-19: Methodological and Regulatory Considerations for a Better Societal Outcome.

Authors:  Olivier Collignon; Carl-Fredrik Burman; Martin Posch; Anja Schiel
Journal:  Clin Pharmacol Ther       Date:  2021-03-16       Impact factor: 6.903

3.  Extracorporeal Blood Purification in Moderate and Severe COVID-19 Patients: A Prospective Cohort Study.

Authors:  Rodney Alexander Rosalia; Petar Ugurov; Dashurie Neziri; Simona Despotovska; Emilija Kostoska; Lidija Veljanovska-Kiridjievska; Dimche Kuzmanov; Aleksandar Trifunovski; Dijana Popevski; Gianluca Villa; Zan Mitrev
Journal:  Blood Purif       Date:  2021-06-14       Impact factor: 2.614

Review 4.  COVID-19 of dialysis patients in Japan: Current status and guidance on preventive measures.

Authors:  Kan Kikuchi; Masaomi Nangaku; Munekazu Ryuzaki; Tomoyuki Yamakawa; Norio Hanafusa; Ken Sakai; Yoshihiko Kanno; Ryoichi Ando; Toshio Shinoda; Hidetomo Nakamoto; Tadao Akizawa
Journal:  Ther Apher Dial       Date:  2020-08       Impact factor: 2.195
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.